Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572929 · ClinicalTrials.gov registry record · Phase 2
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
NCT07572929: Clinical Trial Phase 2 study, sponsored by Medical College of Wisconsin.
NCT07572929 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 450 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07572929, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
Study Summary
This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.
Primary Outcome
All patients will have standard histological analysis of bone marrow biopsies done post-transplant after engraftment, per institutional standard, at one year. For acute leukemia (AML or ALL) or myelodysplastic syndrome, relapse is defined as greater than 5% blasts on histologic analysis of bone marrow biopsy. Among patients assigned to Arm B, institution of any therapy with intent to treat hematologic malignancy will also be considered evidence of relapse.
Interventions
- OTHER No intervention
- DRUG Maintenance Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2034-02-01 |
| Phase | Phase 2 |
What is known before NCT07572929 opens enrollment
NCT07572929 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT07572929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07572929 about?
NCT07572929 is a clinical study titled "A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant". This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual dise...
What is the current status of trial NCT07572929?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2026-08-01. Estimated completion is 2034-02-01.
What interventions are being tested in trial NCT07572929?
The interventions under investigation include: No intervention (OTHER), Maintenance Therapy (DRUG).
Who is sponsoring clinical trial NCT07572929?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07572929's enrollment target sits among peer trials
450 87th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI